ArticleJAMA oncology2023
Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients With Borderline Resectable Pancreatic Cancer-The A021501 Trial-Reply.
Matthew H G Katz et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
1 paper cites it
this papercites it